Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

PI3K and the heterogeneity of small tumour breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.05.12
Views: 3540
Rating:

Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium

Dr Sherene Loi talks to ecancer about the heterogeneity of breast cancer tumours at IMPAKT 2012 in Brussels, May 2012.

 

Technology now allows for the understanding of the cancer genome down to the base pair of certain types of cancer. In small tumour breast cancer, less than 2cm, the tumours have multiple ‘clones’ and these ‘clones’ drive the growth of the tumour. Treatment of one tumour can be the reason for relapses as another tumour can then proliferate.

 

Dr Loi also discusses PI3 kinase, which is essential for cell growth but highly irregular in breast cancer and especially in triple negative breast cancer where no targeted therapies yet exist.

 

Filming Supported by Amgen

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation